Trends Immunol. 2024 Nov 20:S1471-4906(24)00272-2. doi: 10.1016/j.it.2024.11.001. Online ahead of print.
ABSTRACT
The success of T cell-based immunotherapies is limited by exhaustion, which is associated with mitochondrial dysfunction. Baldwin and colleagues show that bone marrow stromal cells (BMSCs) use nanotubes to transfer mitochondria to T cells, which increases mitochondria mass and fitness and boosts antitumor efficacy. The results pave the way to organelle-based therapies against cancer.
PMID:39572338 | DOI:10.1016/j.it.2024.11.001